Mizuho lowered the firm’s price target on Iqvia to $229 from $250 and keeps a Buy rating on the shares. ahead of the Q3 report. The analyst reduced estimates on Walgreens and Iqvia to reflect low visibility in the U.S. Healthcare and Technology and Analytics Solutions segments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IQV:
- Iqvia enters pact with Argenx to provide safety systems, services
- Iqvia price target lowered to $245 from $250 at Barclays
- Iqvia initiated with a Buy at HSBC
Questions or Comments about the article? Write to editor@tipranks.com